Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
La Jolla, CaliforniaAges 18–18 - NCT07511361RecruitingPhase 2
Tonlamarsen for high blood pressure after hospitalization
This study tests an investigational medication (Tonlamarsen) for people who were recently hospitalized for a very severe high blood pressure episode and also have heart or kidney disease. It aims to see if the drug can help control blood pressure after discharge.
Arvada, ColoradoAges 18 years+ - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT07508761RecruitingPhase 1/Phase 2
IPG7236 with Toripalimab for advanced solid tumors
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Shanghai, PuDongXinQuAges 18 years+ - NCT07512427RecruitingPhase 1/Phase 2
Testing OPK-88006 for Fatty Liver Disease
This trial tests a new experimental drug called OPK-88006 to see if it can help treat MASH, a serious liver condition linked to excess fat buildup. The study has two parts: one with healthy volunteers to check safety, and one with people who have signs of fatty liver disease.
Miami, FloridaAges 18–75 - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT07512271Recruiting
AI Education Tool for Breast Cancer Patients
This study tests a new computer-based education module created by artificial intelligence to help breast cancer patients understand their diagnosis and treatment options. The goal is to see if this tool helps patients feel more informed and prepared for their care.
San Francisco, CaliforniaAges 18 years+ - NCT07499544RecruitingPhase 3
Testing Libevitug for chronic hepatitis D
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Garden Grove, CaliforniaAges 12–70 - NCT07502508RecruitingPhase 2
Icovamenib for type 2 diabetes with Ozempic
This trial tests an investigational pill called icovamenib for people with type 2 diabetes who are already on Ozempic but still have high blood sugar. The goal is to see if adding icovamenib helps lower blood sugar more safely.
Birmingham, AlabamaAges 18–70 - NCT07500090RecruitingPhase 3
Study of HBS-301 for idiopathic hypersomnia
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
Birmingham, AlabamaAges 18 years+ - NCT07499362RecruitingPhase 2
Study of Pimicotinib for Japanese Patients with TGCT
This trial tests a new drug called pimicotinib for people in Japan with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. It aims to see if the drug can help with pain and stiffness caused by the tumor.
ChūōkuAges 18 years+ - NCT07505771RecruitingPhase 1
A study of 177Lu-IM-3050 for advanced solid tumors
This trial tests a new treatment called 177Lu-IM-3050 for people with advanced solid tumors that have not responded to or stopped working with standard treatments. The treatment targets a protein called FAP found on some cancer cells and may help shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07503886RecruitingPhase 2
Study of an eye drop for dry eye disease
This trial tests a new eye drop called DFL24498 to see if it helps people with dry eye disease. You may qualify if your dry eye is moderate to severe and other treatments haven't worked well for you.
Chandler, ArizonaAges 18 years+ - NCT07503873RecruitingPhase 2
Study of ublituximab injection for multiple sclerosis
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
BihaćAges 18–65 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT07506863RecruitingPhase 3
Mitapivat for children with transfusion-dependent thalassemia
This study tests a study pill called mitapivat for children aged 1 to 17 with transfusion-dependent thalassemia. The goal is to see if mitapivat can reduce the need for blood transfusions and improve blood counts.
Atlanta, GeorgiaAges 1–17 - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07501039RecruitingPhase 1
First test of BLKR201 in healthy adults
This study tests a new medicine, called BLKR201, for the first time in people. It is given to healthy volunteers to see how safe it is and how the body handles it.
Lincoln, NebraskaAges 18–55 - NCT07498673RecruitingEarly Phase 1
Testing YKST02 for IgA nephropathy
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
Wuhan, HubeiAges 18–75 - NCT07494214RecruitingPhase 1
Study on MDMA for pain relief in healthy people
This trial tests if a single dose of MDMA can reduce pain caused by heat or pressure in healthy volunteers. It aims to see if MDMA might help with certain types of pain that are hard to treat.
BaselAges 18–75 - NCT07497503RecruitingPhase 1
Study of B-3E07 and Forsteo in healthy women
This trial tests a new medicine called B-3E07 together with Forsteo (a bone-strengthening drug) in healthy women. It aims to see if the combination is safe and how the body processes it.
Bayswater, VictoriaAges 18–45 - NCT07491172RecruitingPhase 1
Trial of CTX310 for stubborn high cholesterol and fats
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
Hialeah, FloridaAges 18–75 - NCT07489885RecruitingPhase 2
Study of D-2570 for moderate to severe plaque psoriasis
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
Birmingham, AlabamaAges 18–70
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,290 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.